Detalles de la búsqueda
1.
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Br J Cancer
; 116(11): 1462-1469, 2017 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449008
2.
Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
Br J Cancer
; 115(12): 1520-1529, 2016 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27802454
3.
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 171-9, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25547219
4.
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Acta Oncol
; 54(7): 993-1000, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25924969
5.
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
BMC Cancer
; 14: 624, 2014 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25164437
6.
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Gut
; 62(5): 751-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22773551
7.
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Breast Cancer Res Treat
; 132(3): 863-70, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21667238
8.
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Anticancer Drugs
; 21(1): 94-100, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19770635
9.
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
J Clin Oncol
; 27(33): 5529-37, 2009 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19786670
10.
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
J Clin Oncol
; 27(12): 1999-2006, 2009 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19289619
Resultados
1 -
10
de 10
1
Próxima >
>>